Clinical outcome of one-third-dose depot triptorelin is the same as half-dose depot triptorelin in the long protocol of controlled ovarian stimulation

Journal of Human Reproductive Sciences

Volumn 5, Issue 1, 2012, Pages 14-19

  Li, Yu ^a   Yang, Dongzi ^a   Zhang, Qingxue ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

GnRH agonist; in vitro fertilization; ovarian stimulation; triptorelin

Indexed keywords

CHORIONIC GONADOTROPIN; DIPHERELIN; ESTRADIOL; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN; TRIPTORELIN; UNCLASSIFIED DRUG;

ABORTION; ADULT; ARTICLE; BIRTH RATE; CLINICAL PROTOCOL; CONTROLLED STUDY; CRYOPRESERVATION; DELIVERY; DRUG DOSE COMPARISON; EMBRYO DEVELOPMENT; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; HORMONAL THERAPY; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LIVE BIRTH; LUTEINIZING HORMONE RELEASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; NIDATION; OOCYTE RETRIEVAL; OVULATION INDUCTION; PREGNANCY RATE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 84863664428     PISSN: 09741208     EISSN: 19984766     Source Type: Journal    
DOI: 10.4103/0974-1208.97785     Document Type: Article

References (24)

1. Caspi E, Ron-El R, Golan A, Nachunv A, Herman A, Soffer Y, et al. Results of in vitro fertilization and embryo transfer by combined longacting gonadotrophin-releasing hormone analog D-Trp-6-luteinizing hormone-releasing hormone and gonadotrophins. Fertil Steril 1989;51:95-9.
2. Liu HC, Lai YM, Davis O, Berkeley AS, Graf M, Grifo J, et al. Improved pregnancy outcome with gonadotrophin releasing hormone agonist stimulation is due to the improvement in oocytes quantity rather than quality. J Assist Reprod Genet 1992;9:338-42.
3. Albuquerque LE, Saconato H, Maciel MC. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles. Cochrane Database Syst Rev 2005;25:CD002808.
4. Olivennes F, Righini C, Fanchin R, Torrisi C, Hazout A, Glissant M, et al. A protocol using a low dose of gonadotrophin-releasing hormone agonist might be the best protocol for patients with high follicle-stimulating hormone concentrations on day 3. Hum Reprod 1996;11:1169-72.
5. Janssens RM, Lambalk CB, Vermeiden JP, Schats R, Bernards JM, Rekers-Mombarg LT, et al. Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: A prospective, randomized, double-blind, placebo-controlled study. Hum Reprod 2000;15:2333-40.
6. Dal Prato L, Borini A, Trevisi MR, Bonu MA, Sereni E, Flamigni C. Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: A randomized study. Hum Reprod 2001;16:1409-14.
7. Yim SF, Lok IH, Cheung LP, Briton-Jones CM, Chiu TT, Haines CJ. Dosefinding study for the use of long-acting gonadotrophin-releasing hormone analogues prior to ovarian stimulation for IVF. Hum Reprod 2001;16:492-4.
8. Dal Prato L, Borini A, Coticchio G, Cattoli M, Flamigni C. Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: A randomized study. Hum Reprod 2004;19:2200-5.
9. Isikoglu M, Ozdem S, Berkkanoglu M, Jamal H, Senturk Z, Ozgur K. Single-dose depot leuprolide is as efficient as daily short-acting leuprolide in ICSI cycles. Hum Reprod 2007;22:1657-61.
10. Safdarian L, Mohammadi FS, Alleyassin A, Aghahosseini M, Meysamie A, Rahimi E. Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: A randomized doubleblind clinical trial (NCT00461916). Hum Reprod 2007;22:2449-54.
11. Magli MC, Van den Abbeel E, Lundin K, Royere D, Van der Elst J, Gianaroli L; Committee of the Special Interest Group on Embryology. Revised guidelines for good practice in IVF laboratories. Hum Reprod 2008;23:1253-62.
12. Hu Y, Maxon WS, Hoffman DI, Ory SJ, Eager S, Dupre J, et al. Maximizing pregnancy rates and limiting higher-order multiple conceptions by determining the optimal number of embryos to transfer based on quality. Fertil Steril 1998;69:650-7.
13. Balasch J, Gomez F, Casamitjana R, Carmona F, Rivera F, Vanrell JA. Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot. Hum Reprod 1992;7:1230-4.
14. Jayaprakasan K, Campbell BK, Hopkisson JF, Clewes JS, Johnson IR, Raine-Fenning NJ. Effect of pituitary desensitization on the early growing follicular cohort estimated using anti-Mullerian hormone. Hum Reprod 2008;23:2577-83.
15. Weston AM, Zelinski-Wooten MB, Hutchison JS, Stouffer RL, Wolf DP. Development potential of embryos produced by in-vitro fertilization from gonadotrophin-releasing hormone antagonist-treated macaques stimulated with recombinant human follicle stimulating hormone alone or in combination with luteinizing hormone. Hum Reprod 1996;11:608-13.
16. Shoham Z, Balen A, Patel A. Results of ovulation induction using human menopausal gonadotrophin and purified follicle-stimulating hormone in hypogonadotrophic hypogonadism patients. Fertil Steril 1991;56:1048-53.
17. Balasch J, Miro F, Burzaco I. The role of luteinizing hormone in human follicle development and oocyte fertility: Evidence from in vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicule stimulating hormone. Hum Reprod 1995;10:1678-83.
18. Fleming R, Lloyd F, Herbert M, Fenwick J, Griffith T, Murdoch A. Effect of profound suppression of LH during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified FSH. Hum Reprod 1998;13:1788-92.
19. Westergaard LG, Laursen SB, Anderson CY. Increased risk of early pregnancy loss by profound suppression of luteinising hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000;15:1003-8.
20. Humaidan P, Bungum L, Bungum M, Andersen CY. Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation. Hum Reprod 2002;17:2016-21.
21. Tesarik J, Hazout A, Mendoza C. Luteining hormone affects uterine receptivity independently of ovarian function. RBM Online 2003;7:59-64.
22. Bourgain C, Ubaldi F, Tavaniotou A, Smitz J, Van Steirteghem AC, Devroey P. Endometrial hormone receptors and proliferation index in the periovulatory phase of stimulated embryo transfer cycles in comparison with natural cycles and relation to clinical pregnancy outcome. Fertil Steril 2002;78:237-44.
23. Dor J, Bider D, Shulman A, Levron J, Shine S, Mashiach S, et al. Effects of gonadotrophin-releasing hormone agonists on human ovarian steroid secretion in vivo and in vitro-results of a prospective, randomized in-vitro fertilization study. Hum Reprod 2000;15:1225-30.
24. Gerrero H, Stein P, Asch R, de Fried E, Tesone M. Effect of a gonodotropinreleasing hormone agonist on luteinizing homone receptors and steroidogenesis in ovarian cells. Fertil Steril 1993;59:803-8.